Regeneron Pharmaceuticals (Nasdaq:REGN) - Aandelenkoers, Nieuws & Analyse

REGN Overzicht aandelen

Regeneron Pharmaceuticals, Inc. ontdekt, bedenkt, ontwikkelt, produceert en verkoopt wereldwijd geneesmiddelen voor de behandeling van verschillende ziekten. Meer informatie

REGN fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	1/6
Prestaties in het verleden	5/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 65.3% onder onze schatting van de reële waarde

De winst zal naar verwachting met 7.57% per jaar groeien

De winst groeide het afgelopen jaar met 16.6%

Analisten zijn het erover eens dat de aandelenkoers met 45% zal stijgen

Risicoanalyse

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Regeneron Pharmaceuticals, Inc. Concurrenten

Amgen

NasdaqGS:AMGN

US$150.5b

Biogen

NasdaqGS:BIIB

US$22.6b

AbbVie

NYSE:ABBV

US$294.4b

Horizon Therapeutics

NasdaqGS:HZNP

US$26.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Regeneron Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$743.35
52 Week Hoogtepunt	US$1,211.20
52 Week Laag	US$736.01
Bèta	0.14
11 maand verandering	-23.25%
3 maanden verandering	-37.41%
1 Jaar Verandering	-7.05%
33 jaar verandering	14.68%
5 jaar verandering	100.05%
Verandering sinds IPO	3,418.82%

Recent nieuws en updates

Regeneron: The Biotech Stock To Buy Now

Nov 19

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Recent updates

Regeneron: The Biotech Stock To Buy Now

Nov 19

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Rendement voor aandeelhouders

	REGN	US Biotechs	US Markt
7D	-7.6%	-6.5%	-1.0%
1Y	-7.0%	14.6%	30.3%

Rendement versus industrie: REGN presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 14.6 % opleverde.

Rendement versus markt: REGN presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.3 % opleverde.

Prijsvolatiliteit

Is REGN's price volatile compared to industry and market?
REGN volatility
REGN Average Weekly Movement	3.8%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: REGN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van REGN is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1988	14,165	Leonard Schleifer	www.regeneron.com

Regeneron Pharmaceuticals, Inc. ontdekt, bedenkt, ontwikkelt, produceert en verkoopt wereldwijd geneesmiddelen voor de behandeling van verschillende ziekten. De producten van het bedrijf omvatten EYLEA-injectie voor de behandeling van leeftijdsgebonden maculadegeneratie en diabetisch macula-oedeem; bijziend choroïdale neovascularisatie; diabetische retinopathie; neovasculair glaucoom; en retinopathie van prematuriteit. Het levert ook Dupixent injectie voor de behandeling van atopische dermatitis en astma bij volwassenen en kinderen; Libtayo injectie voor de behandeling van metastatisch of lokaal gevorderd cutaan plaveiselcelcarcinoom; Praluent injectie voor heterozygote familiaire hypercholesterolemie of klinische atherosclerotische cardiovasculaire aandoeningen bij volwassenen; REGEN-COV voor covid-19; en Kevzara oplossing voor de behandeling van reumatoïde artritis bij volwassenen.

Regeneron Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Regeneron Pharmaceuticals zich tot de beurswaarde?
REGN fundamentele statistieken
Marktkapitalisatie	US$80.11b
Inkomsten(TTM)	US$4.65b
Inkomsten(TTM)	US$13.85b

17.2x

Koers/Winstverhouding

5.8x

P/S-verhouding

Is REGN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
REGN resultatenrekening (TTM)
Inkomsten	US$13.85b
Kosten van inkomsten	US$6.82b
Brutowinst	US$7.03b
Overige uitgaven	US$2.37b
Inkomsten	US$4.65b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	43.26
Brutomarge	50.75%
Nettowinstmarge	33.61%
Schuld/Eigen Vermogen Verhouding	6.8%

Hoe presteerde REGN op de lange termijn?

Bekijk historische prestaties en vergelijking

REGN Overzicht aandelen

Beloningen

Risicoanalyse

Regeneron Pharmaceuticals, Inc. Concurrenten

NasdaqGS:AMGN

US$150.5b

NasdaqGS:BIIB

US$22.6b

NYSE:ABBV

US$294.4b

NasdaqGS:HZNP

US$26.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Regeneron: The Biotech Stock To Buy Now

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Regeneron: The Biotech Stock To Buy Now

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Senior VP of Finance & CFO recently sold US$6.4m worth of stock

Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron Stock: Valuation Now Demands More Growth

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Regeneron Provides Update on Biologics License Application for Linvoseltamab

Executive Vice President of Research exercised options and sold US$15m worth of stock

Insider recently sold US$5.6m worth of stock

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Executive VP exercised options and sold US$5.6m worth of stock

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Co-Founder exercised options and sold US$1.0m worth of stock

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Co-Founder exercised options and sold US$104m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

New minor risk - Shareholder dilution

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Executive Vice President of Research exercised options and sold US$11m worth of stock

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Co-Founder exercised options and sold US$68m worth of stock

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider exercised options and sold US$14m worth of stock